---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-26-000046"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2026-05-14T12:36:07+00:00"
generated_at: "2026-05-14T12:41:14.965479+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GRI Bio Q1 net loss $2.0M; Phase 2a data show zero cough, improved lung function in IPF

## Summary
- Net loss of $2.0M for Q1 2026 vs. $3.0M in Q1 2025; cash $11.0M, runway into Q2 2027.
- Phase 2a of GRI-0621 in IPF: zero cough in active arm vs 25% placebo; 61% less diarrhea vs placebo despite 67% more nintedanib use.
- Exploratory FVC improvement: +99 mL overall, +139 mL in SOC combination subset vs placebo+SOC.
- Raised ~$6.8M gross via ATM facility in Q1 2026; advancing GRI-0621 toward pivotal studies, GRI-0803 toward IND.
- No SAEs in active arm; single SAE in placebo; patent applications filed based on new data.

## SEC filing metadata
- accession: 0001824293-26-000046
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2026-05-14T12:36:07+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429326000046/0001824293-26-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429326000046/val-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-26-000046
- JSON: https://secwatch.observer/filing/0001824293-26-000046.json
- Plain text: https://secwatch.observer/filing/0001824293-26-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.